# Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth

> **NCT02251483** · NA · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Diarrhea Predominant Irritable Bowel Syndrome
- Small Intestinal Bacterial Overgrowth

## Interventions

- **OTHER:** Serum-derived bovine immunoglobulin protein isolate (SBI)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02251483
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2015-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251483, "Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02251483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*